A common rheumatoid arthritis medication, called tofacitnib citrate, successfully treats severe eczema.
Supposedly “unbeatable” eczema (atopic dermatitis) can be successfully treated using a common rheumatoid arthritis (RA) drug, suggest findings published in the Journal of the American Academy of Dermatology.
Researchers from Yale University studied six patients in order to evaluate the efficacy of the oral Janus kinase (JAK) inhibitor tofacitinib in the treatment of moderate to severe atopic dermatitis. The patients had all failed standard atopic dermatitis treatment. The researchers noted that the existing treatments for atopic dermatitis are often inadequate for the patients who suffer from it.
The patients were treated with tofacitinib citrate and their response to the treatment was assessed using the Scoring of Atopic Dermatitis index.
In all patients included in the study, tofacitinib improved sleep and reduced itch significantly. The patients also showed reduced redness and thickening of the skin. The scoring index of the patients decreased from 66.6 percent, from 36.5 to 12.2 between weeks 8 and 29 of treatment. There were no adverse events reported by the participants.
Read Full Article: Rheumatoid Arthritis Drug Tofacitinib Can Successfully Treat Eczema